產(chǎn)品詳情
簡(jiǎn)單介紹：
Anti-Nanos3抗體產(chǎn)品質(zhì)量穩(wěn)定，實(shí)驗(yàn)效果明顯，貨期快，價(jià)格優(yōu)惠，歡迎垂詢訂購(gòu)！我公司長(zhǎng)期供應(yīng)**組化抗體、WB抗體、**組化試劑盒和抗體試驗(yàn)所需全部相關(guān)試劑、熒光標(biāo)記抗體、單克隆抗體、多克隆抗體、各種標(biāo)記的二抗IgG/IgM/IgD/IgA等科研實(shí)驗(yàn)抗體。Anti-Nanos3抗體用于**組化實(shí)驗(yàn),WB實(shí)驗(yàn),相應(yīng)的標(biāo)記抗體有HRP標(biāo)記抗體,FITC標(biāo)記,BIO等。
詳情介紹：
Rabbit Anti-Nanos3
Cat. Number:
Anti-Nanos3抗體KL-10227R
Quantity size:
0.2ml
Concentration:
1mg/ml Buffer = 0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol.
Background:
Nidogens are highly conserved proteins present in vertebrate and invertebrate basement membranes. Nidogens connect the Laminin and Collagen IV networks and integrate other proteins into the membrane. In mammals, Anti-Nanos3抗體two Nidogen proteins, Nidogen and Nidogen-2, interact at comparable levels with Collagen I, IV and Perlecan, serving to stabilize basement membranes and playing a major role in embryogenesis. The two isoforms have a similar shape, consisting of three globular domains, and co-localize in vessel walls and other basement membrane zones. Nidogen-2 is a cell adhesion protein glycosylated at nitrogen and oxygen sites, and is widely distributed in basement membranes in heart, placenta, bone and, to a lesser extent, in pancreas, kidney and skeletal muscle.
Also known as:
NANOS3; NANOS 3; NANOS-3; NOS3; Anti-Nanos3抗體NOS-3; Nanos homolog 3; NANO3_HUMAN.
Specificity:
●
Rabbit Polyclonal IgG, affinity purified by Protein A.
●
Reacts with: Human, Mouse, Rat, Anti-Nanos3抗體Pig, Cow, Sheep, .
●
Immunogen: KLH conjugated synthetic peptide derived from human Nanos3.
●
Predicted Molecular Weight: 19kDa.
Storage:
Shipped at 4℃, Store at -20℃ (Avoid repeated freeze/thaw cycles).
Application:
WB=1:100-500 ELISA=1:500-1000 IHC-P=1:100-500 IHC-F=1:100-500 ICC=1:100-500 IF=1:100-500
Not yet tested in other applications. Anti-Nanos3抗體
Optimal working dilutions must be determined by the end user.
Not yet tested in other applications. Anti-Nanos3抗體
Optimal working dilutions must be determined by the end user.
